<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185298</url>
  </required_header>
  <id_info>
    <org_study_id>20191298</org_study_id>
    <nct_id>NCT04185298</nct_id>
  </id_info>
  <brief_title>mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults With Amnestic Mild Cognitive Impairment</brief_title>
  <acronym>mSIM</acronym>
  <official_title>Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Wayne Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Wayne Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mSIM study involves developing and conducting feasibility testing of a web-based
      application that will deliver mobile-based simultaneous exercise and memory skills training
      program (mSIM) for amnesic Mild Cognitive Impairment (aMCI) patients.

      The randomized control trial (RCT) will evaluate the efficacy of mSIM on memory performance
      and everyday functioning using 2 study arms (Group 1 activity monitoring control (via Fitbit)
      (CON) vs Group 2 mSIM intervention plus activity monitoring via Fitbit). mSIM treatment
      response will be evaluated using neuropsychological and functional evaluation. Concentration
      levels of peripheral biomarkers Brain-derived neurotrophic factor (BDNF) and norepinephrine
      (NE) also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to create a web-based cognitive compensatory, and predominately
      memory skills, training course that is delivered on a mobile device and compatible with use
      on a stationary bicycle and test its efficacy on memory and functional ability.

      Participants will be recruited from the Pacific Brain Health Center in Santa Monica, which is
      a high-volume memory-care and dementia outpatient clinic within a large physician medical
      group affiliated with Providence Saint John's Health Center. Up to five participants will be
      course beta testers. They will receive a truncated version of the course and will provide
      detailed feedback. 30 participants will be randomized into one of two groups. Group 1
      (control arm) will have their physical activity levels continuously monitored (via Fitbit).
      Participants will receive the Experimental Research Subject's Bill of Rights prior to signing
      the informed consent form (ICF), authorization of use and disclosure of protected health
      information (PHI), and authorization of medical record release for the subject's treating
      physician, will be obtained from each participants prior to enrolling in the study. A copy of
      all signed ICF's will be given to the participants, and the investigator will retain the
      original.

      Group 2 (active arm) will receive the mSIM intervention plus activity monitoring (via
      Fitbit). Group 2 will first undergo 2 weeks of an exercise ramp-up (2x/week for 30 minutes)
      where they will increase their aerobic intensity from 50% by 5% each session until they reach
      65% HRR and can sustain that heart rate for 40 minutes, which will be the intensity for the
      training. After the ramp-up phase the mSIM participants will begin the 12-week intervention,
      comprised of 2 60-minute sessions/week. mSIM treatment response will be evaluated using
      neuropsychological and functional evaluation. Assessments will occur at baseline and 17
      weeks. Concentration levels of peripheral biomarkers BDNF and NE at baseline and after 17
      -weeks will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will include two arms: Arm 1: activity monitoring only control (CON), Arm 2: active intervention with mSIM program (mSIM) plus activity monitoring (via Fitbit), to evaluate the efficacy of the mSIM intervention on memory performance and everyday functioning. The 'Activity monitoring only' arm will serve as the control group. Study objectives include measuring treatment related changes in memory performance and everyday functioning along with putative biomarkers of the behavioral changes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Memory Function Composite Score</measure>
    <time_frame>Baseline and 17-weeks</time_frame>
    <description>Global Z-Score including results from RAVLT (Rey's Auditory Verbal Learning Test), Wechsler Memory Scale Fourth Edition (WMS-IV) Logical Memory and Visual Reproduction tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Abilities</measure>
    <time_frame>Baseline and 17-weeks</time_frame>
    <description>Assessed using the Functional Activities Questionnaire (FAQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting brain-derived neurotrophic factor (BDNF)</measure>
    <time_frame>Baseline and 17-weeks</time_frame>
    <description>Resting level of serum BDNF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting norepinephrine (NE)</measure>
    <time_frame>Baseline and 17-weeks</time_frame>
    <description>Resting level of Salivary alpha-amylase activity (sAA) -derived norepinephrine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amnestic Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1 (No treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: Participants will have continuous activity monitoring (via Fitbit)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>mSIM intervention plus activity monitoring</intervention_name>
    <description>Participants will receive the full mSIM intervention and be monitored (via Fitbit)</description>
    <arm_group_label>Group 1 (No treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Activity monitoring</intervention_name>
    <description>Participants will have activity monitored (via Fitbit)</description>
    <arm_group_label>Group 2 (Experimental)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects must be age 50 to 80 at time of informed consent.

          -  Subjects must have undergone an evaluation, including clinical assessment to confirm
             aMCI diagnosis as part of their ongoing medical treatment within 6 months of
             enrollment to this study.

          -  Subjects of any gender, race or ethnicity are eligible to enroll in the study.

          -  Subjects must be proficient in spoken and written English for consenting as well as
             for study participation since the intervention in this study is currently only
             available in English.

          -  Subjects with medical conditions must be stable for these conditions. Stable control
             on medication is acceptable.

          -  If subjects at screening answers &quot;yes&quot; to any question on the PAR-Q, they will need to
             obtain clearance from a physician to participate in a moderate aerobic exercise.
             program, which was a sufficient safety measure employed in our pilot SIM study.

          -  Subjects, with or without assistance, must be able to use a computer and web
             interface. If assistance is needed, it must be readily available to them.

          -  Subjects are required to have internet with wifi at the location of their mSIM
             training.

          -  Subject must have normal visual acuity (or corrected to normal) and normal color
             vision as indicated by self-report.

          -  Subject must have adequate hearing acuity as indicated by self-report.

          -  Subject must have adequate motor capacity to use a mobile phone/iPad/computer as
             indicated by self-report.

        Exclusion Criteria

          -  Subjects must not have an existing diagnosis of a neurodegenerative disorder (e.g.,
             Alzheimer's Disease, Lewy Body Dementia, Frontal-Temporal Dementia).

          -  Subjects must not have a prior diagnosis that might impact cognition and movement
             abilities including: cardiovascular, respiratory, illness or injury, substance abuse,
             schizophrenia, bipolar disorder, or other neurological diseases.

          -  Subjects must not have a Mini Mental State Exam (MMSE) below 19.

          -  Subjects must not have a Clinical Dementia Rating (CDR) global score of 2 or above 2.

          -  Subjects must not have a Montreal Cognitive Assessment (MoCA)42 score of below 20 or
             during their baseline evaluation.

          -  Subjects must not demonstrate a progression of aMCI to dementia at baseline based on
             the best judgement of a study Clinical Neuropsychologist.

          -  Subjects must not answer in the affirmative to any PAR-Q questionnaire and be unable
             to provide medical clearance from their physician.

          -  Subjects must not be unable to pass the cardiovascular fitness test during their
             baseline evaluation.

          -  Subjects must not have EKG abnormalities found during the subject's baseline
             evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah McEwen, PhD</last_name>
    <phone>310-738-1551</phone>
    <email>sarah.mcewen@providence.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Bramen, PhD</last_name>
    <phone>310-829-8043</phone>
    <email>jennifer.bramen@providence.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Brain Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bramen, PhD</last_name>
      <phone>310-829-8043</phone>
      <email>jbramen@pacificneuro.org</email>
    </contact>
    <contact_backup>
      <last_name>David H Merrill, MD, PhD</last_name>
      <phone>(310) 582-7641</phone>
      <email>david.merrill@providence.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs362/en/</url>
    <description>WHO definitions</description>
  </link>
  <link>
    <url>https://www.pearsonclinical.co.uk/Psychology/AdultCognitionNeuropsychologyandLanguage/AdultMemory/RivermeadBehaviouralMemoryTestThirdEditionRBMT3/RivermeadBehaviouralMemoryTestThirdEditionRBMT3.aspx</url>
    <description>Rivermead Behavioural Memory Test - Third Edition (RBMT-3)</description>
  </link>
  <link>
    <url>https://www.alz.org/careplanning/downloads/functional-activities-questionnaire.pdf</url>
    <description>Use of the Functional Activities Questionnaire in Older Adults with Dementia</description>
  </link>
  <link>
    <url>https://www.baycrest.org/Baycrest_Centre/media/content/form_files/MMQ-Manual-2018_ebook.pdf</url>
    <description>Multifactorial Memory Questionnaire</description>
  </link>
  <reference>
    <citation>Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, Padovani A. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry. 2007 Dec;22(12):1217-22.</citation>
    <PMID>17562522</PMID>
  </reference>
  <reference>
    <citation>Naismith SL, Glozier N, Burke D, Carter PE, Scott E, Hickie IB. Early intervention for cognitive decline: is there a role for multiple medical or behavioural interventions? Early Interv Psychiatry. 2009 Feb;3(1):19-27. doi: 10.1111/j.1751-7893.2008.00102.x. Review.</citation>
    <PMID>21352171</PMID>
  </reference>
  <reference>
    <citation>Merrill DA, Small GW. Prevention in psychiatry: effects of healthy lifestyle on cognition. Psychiatr Clin North Am. 2011 Mar;34(1):249-61. doi: 10.1016/j.psc.2010.11.009. Epub 2010 Dec 16. Review.</citation>
    <PMID>21333851</PMID>
  </reference>
  <reference>
    <citation>Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct;43-44:38-53. doi: 10.1016/j.mam.2015.06.003. Epub 2015 Jun 10. Review.</citation>
    <PMID>26070444</PMID>
  </reference>
  <reference>
    <citation>Smith PJ, Blumenthal JA, Hoffman BM, Cooper H, Strauman TA, Welsh-Bohmer K, Browndyke JN, Sherwood A. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med. 2010 Apr;72(3):239-52. doi: 10.1097/PSY.0b013e3181d14633. Epub 2010 Mar 11. Review.</citation>
    <PMID>20223924</PMID>
  </reference>
  <reference>
    <citation>Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, Macchi C. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011 Jan;269(1):107-17. doi: 10.1111/j.1365-2796.2010.02281.x. Epub 2010 Sep 10. Review.</citation>
    <PMID>20831630</PMID>
  </reference>
  <reference>
    <citation>Huckans M, Hutson L, Twamley E, Jak A, Kaye J, Storzbach D. Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: working toward a theoretical model and evidence-based interventions. Neuropsychol Rev. 2013 Mar;23(1):63-80. doi: 10.1007/s11065-013-9230-9. Epub 2013 Mar 8. Review.</citation>
    <PMID>23471631</PMID>
  </reference>
  <reference>
    <citation>Snowden M, Steinman L, Mochan K, Grodstein F, Prohaska TR, Thurman DJ, Brown DR, Laditka JN, Soares J, Zweiback DJ, Little D, Anderson LA. Effect of exercise on cognitive performance in community-dwelling older adults: review of intervention trials and recommendations for public health practice and research. J Am Geriatr Soc. 2011 Apr;59(4):704-16. doi: 10.1111/j.1532-5415.2011.03323.x. Epub 2011 Mar 25. Review.</citation>
    <PMID>21438861</PMID>
  </reference>
  <reference>
    <citation>Kramer AF, Colcombe S. Fitness Effects on the Cognitive Function of Older Adults: A Meta-Analytic Study-Revisited. Perspect Psychol Sci. 2018 Mar;13(2):213-217. doi: 10.1177/1745691617707316.</citation>
    <PMID>29592650</PMID>
  </reference>
  <reference>
    <citation>Bamidis PD, Vivas AB, Styliadis C, Frantzidis C, Klados M, Schlee W, Siountas A, Papageorgiou SG. A review of physical and cognitive interventions in aging. Neurosci Biobehav Rev. 2014 Jul;44:206-20. doi: 10.1016/j.neubiorev.2014.03.019. Epub 2014 Apr 4. Review.</citation>
    <PMID>24705268</PMID>
  </reference>
  <reference>
    <citation>Zhu X, Yin S, Lang M, He R, Li J. The more the better? A meta-analysis on effects of combined cognitive and physical intervention on cognition in healthy older adults. Ageing Res Rev. 2016 Nov;31:67-79. doi: 10.1016/j.arr.2016.07.003. Epub 2016 Jul 14. Review.</citation>
    <PMID>27423932</PMID>
  </reference>
  <reference>
    <citation>Law LL, Barnett F, Yau MK, Gray MA. Effects of combined cognitive and exercise interventions on cognition in older adults with and without cognitive impairment: a systematic review. Ageing Res Rev. 2014 May;15:61-75. doi: 10.1016/j.arr.2014.02.008. Epub 2014 Mar 12. Review.</citation>
    <PMID>24632497</PMID>
  </reference>
  <reference>
    <citation>Karssemeijer EGA, Aaronson JA, Bossers WJ, Smits T, Olde Rikkert MGM, Kessels RPC. Positive effects of combined cognitive and physical exercise training on cognitive function in older adults with mild cognitive impairment or dementia: A meta-analysis. Ageing Res Rev. 2017 Nov;40:75-83. doi: 10.1016/j.arr.2017.09.003. Epub 2017 Sep 12. Review.</citation>
    <PMID>28912076</PMID>
  </reference>
  <reference>
    <citation>McEwen SC, Siddarth P, Rahi B, Kim Y, Mui W, Wu P, Emerson ND, Lee J, Greenberg S, Shelton T, Kaiser S, Small GW, Merrill DA. Simultaneous Aerobic Exercise and Memory Training Program in Older Adults with Subjective Memory Impairments. J Alzheimers Dis. 2018;62(2):795-806. doi: 10.3233/JAD-170846. Erratum in: J Alzheimers Dis. 2019;67(3):1107.</citation>
    <PMID>29480182</PMID>
  </reference>
  <reference>
    <citation>Black JE, Isaacs KR, Anderson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5568-72.</citation>
    <PMID>1695380</PMID>
  </reference>
  <reference>
    <citation>van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13427-31.</citation>
    <PMID>10557337</PMID>
  </reference>
  <reference>
    <citation>Kleim JA, Markham JA, Vij K, Freese JL, Ballard DH, Greenough WT. Motor learning induces astrocytic hypertrophy in the cerebellar cortex. Behav Brain Res. 2007 Mar 28;178(2):244-9. Epub 2007 Jan 25.</citation>
    <PMID>17257689</PMID>
  </reference>
  <reference>
    <citation>Hötting K, Röder B. Beneficial effects of physical exercise on neuroplasticity and cognition. Neurosci Biobehav Rev. 2013 Nov;37(9 Pt B):2243-57. doi: 10.1016/j.neubiorev.2013.04.005. Epub 2013 Apr 25. Review.</citation>
    <PMID>23623982</PMID>
  </reference>
  <reference>
    <citation>Lista I, Sorrentino G. Biological mechanisms of physical activity in preventing cognitive decline. Cell Mol Neurobiol. 2010 May;30(4):493-503. doi: 10.1007/s10571-009-9488-x. Epub 2009 Dec 30. Review.</citation>
    <PMID>20041290</PMID>
  </reference>
  <reference>
    <citation>Novkovic T, Mittmann T, Manahan-Vaughan D. BDNF contributes to the facilitation of hippocampal synaptic plasticity and learning enabled by environmental enrichment. Hippocampus. 2015 Jan;25(1):1-15. doi: 10.1002/hipo.22342. Epub 2014 Aug 28.</citation>
    <PMID>25112659</PMID>
  </reference>
  <reference>
    <citation>Vaynman S, Ying Z, Gómez-Pinilla F. Exercise induces BDNF and synapsin I to specific hippocampal subfields. J Neurosci Res. 2004 May 1;76(3):356-62.</citation>
    <PMID>15079864</PMID>
  </reference>
  <reference>
    <citation>Gomez-Pinilla F, Vaynman S, Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur J Neurosci. 2008 Dec;28(11):2278-87. doi: 10.1111/j.1460-9568.2008.06524.x.</citation>
    <PMID>19046371</PMID>
  </reference>
  <reference>
    <citation>Neeper SA, Gómez-Pinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. Nature. 1995 Jan 12;373(6510):109.</citation>
    <PMID>7816089</PMID>
  </reference>
  <reference>
    <citation>Gunstad J, Benitez A, Smith J, Glickman E, Spitznagel MB, Alexander T, Juvancic-Heltzel J, Murray L. Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. J Geriatr Psychiatry Neurol. 2008 Sep;21(3):166-70. doi: 10.1177/0891988708316860. Epub 2008 May 23.</citation>
    <PMID>18503034</PMID>
  </reference>
  <reference>
    <citation>Erickson KI, Miller DL, Roecklein KA. The aging hippocampus: interactions between exercise, depression, and BDNF. Neuroscientist. 2012 Feb;18(1):82-97. doi: 10.1177/1073858410397054. Epub 2011 Apr 29. Review.</citation>
    <PMID>21531985</PMID>
  </reference>
  <reference>
    <citation>Nascimento CM, Pereira JR, de Andrade LP, Garuffi M, Talib LL, Forlenza OV, Cancela JM, Cominetti MR, Stella F. Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res. 2014;11(8):799-805.</citation>
    <PMID>25212919</PMID>
  </reference>
  <reference>
    <citation>McMorris T, Davranche K, Jones G, Hall B, Corbett J, Minter C. Acute incremental exercise, performance of a central executive task, and sympathoadrenal system and hypothalamic-pituitary-adrenal axis activity. Int J Psychophysiol. 2009 Sep;73(3):334-40. doi: 10.1016/j.ijpsycho.2009.05.004. Epub 2009 May 18.</citation>
    <PMID>19454298</PMID>
  </reference>
  <reference>
    <citation>Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2007 Mar;28(3):327-35. Epub 2006 Mar 29.</citation>
    <PMID>16574280</PMID>
  </reference>
  <reference>
    <citation>Klimesch W, Sauseng P, Hanslmayr S. EEG alpha oscillations: the inhibition-timing hypothesis. Brain Res Rev. 2007 Jan;53(1):63-88. Epub 2006 Aug 1. Review.</citation>
    <PMID>16887192</PMID>
  </reference>
  <reference>
    <citation>Richard Clark C, Veltmeyer MD, Hamilton RJ, Simms E, Paul R, Hermens D, Gordon E. Spontaneous alpha peak frequency predicts working memory performance across the age span. Int J Psychophysiol. 2004 Jun;53(1):1-9.</citation>
    <PMID>15172130</PMID>
  </reference>
  <reference>
    <citation>Vlahou EL, Thurm F, Kolassa IT, Schlee W. Resting-state slow wave power, healthy aging and cognitive performance. Sci Rep. 2014 May 29;4:5101. doi: 10.1038/srep05101.</citation>
    <PMID>24869503</PMID>
  </reference>
  <reference>
    <citation>Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res Brain Res Rev. 1999 Apr;29(2-3):169-95. Review.</citation>
    <PMID>10209231</PMID>
  </reference>
  <reference>
    <citation>Li Y, Zhao Z, Cai J, Gu B, Lv Y, Zhao L. The Frequency-Dependent Aerobic Exercise Effects of Hypothalamic GABAergic Expression and Cardiovascular Functions in Aged Rats. Front Aging Neurosci. 2017 Jun 30;9:212. doi: 10.3389/fnagi.2017.00212. eCollection 2017.</citation>
    <PMID>28713263</PMID>
  </reference>
  <reference>
    <citation>Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, Nation DA, Libon DJ, Au R, Galasko D, Salmon DP. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis. 2014;42(1):275-89. doi: 10.3233/JAD-140276.</citation>
    <PMID>24844687</PMID>
  </reference>
  <reference>
    <citation>Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, Salmon DP. Neuropsychological contributions to the early identification of Alzheimer's disease. Neuropsychol Rev. 2008 Mar;18(1):73-90. doi: 10.1007/s11065-008-9054-1. Epub 2008 Mar 18. Review.</citation>
    <PMID>18347989</PMID>
  </reference>
  <reference>
    <citation>Clark LR, Delano-Wood L, Libon DJ, McDonald CR, Nation DA, Bangen KJ, Jak AJ, Au R, Salmon DP, Bondi MW. Are empirically-derived subtypes of mild cognitive impairment consistent with conventional subtypes? J Int Neuropsychol Soc. 2013 Jul;19(6):635-45. doi: 10.1017/S1355617713000313. Epub 2013 Apr 3.</citation>
    <PMID>23552486</PMID>
  </reference>
  <reference>
    <citation>Edmonds EC, Delano-Wood L, Clark LR, Jak AJ, Nation DA, McDonald CR, Libon DJ, Au R, Galasko D, Salmon DP, Bondi MW; Alzheimer's Disease Neuroimaging Initiative. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement. 2015 Apr;11(4):415-24. doi: 10.1016/j.jalz.2014.03.005. Epub 2014 May 22.</citation>
    <PMID>24857234</PMID>
  </reference>
  <reference>
    <citation>Nuriel T, Angulo SL, Khan U, Ashok A, Chen Q, Figueroa HY, Emrani S, Liu L, Herman M, Barrett G, Savage V, Buitrago L, Cepeda-Prado E, Fung C, Goldberg E, Gross SS, Hussaini SA, Moreno H, Small SA, Duff KE. Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. Nat Commun. 2017 Nov 13;8(1):1464. doi: 10.1038/s41467-017-01444-0.</citation>
    <PMID>29133888</PMID>
  </reference>
  <reference>
    <citation>Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, Delis DC. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry. 2009 May;17(5):368-75. doi: 10.1097/JGP.0b013e31819431d5.</citation>
    <PMID>19390294</PMID>
  </reference>
  <reference>
    <citation>Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.</citation>
    <PMID>15817019</PMID>
  </reference>
  <reference>
    <citation>Miller KJ, Siddarth P, Gaines JM, Parrish JM, Ercoli LM, Marx K, Ronch J, Pilgram B, Burke K, Barczak N, Babcock B, Small GW. The memory fitness program: cognitive effects of a healthy aging intervention. Am J Geriatr Psychiatry. 2012 Jun;20(6):514-23. doi: 10.1097/JGP.0b013e318227f821.</citation>
    <PMID>21765343</PMID>
  </reference>
  <reference>
    <citation>Colcombe SJ, Erickson KI, Raz N, Webb AG, Cohen NJ, McAuley E, Kramer AF. Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol A Biol Sci Med Sci. 2003 Feb;58(2):176-80.</citation>
    <PMID>12586857</PMID>
  </reference>
  <reference>
    <citation>Foster C, Jackson AS, Pollock ML, Taylor MM, Hare J, Sennett SM, Rod JL, Sarwar M, Schmidt DH. Generalized equations for predicting functional capacity from treadmill performance. Am Heart J. 1984 Jun;107(6):1229-34.</citation>
    <PMID>6720550</PMID>
  </reference>
  <reference>
    <citation>Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG, Tongiorgi E. A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Sci Rep. 2015 Dec 10;5:17989. doi: 10.1038/srep17989.</citation>
    <PMID>26656852</PMID>
  </reference>
  <reference>
    <citation>Segal SK, Cotman CW, Cahill LF. Exercise-induced noradrenergic activation enhances memory consolidation in both normal aging and patients with amnestic mild cognitive impairment. J Alzheimers Dis. 2012;32(4):1011-8. doi: 10.3233/JAD-2012-121078.</citation>
    <PMID>22914593</PMID>
  </reference>
  <reference>
    <citation>Will PM, Walter JD. Exercise testing: improving performance with a ramped Bruce protocol. Am Heart J. 1999 Dec;138(6 Pt 1):1033-7.</citation>
    <PMID>10577432</PMID>
  </reference>
  <reference>
    <citation>Balady GJ, Chaitman B, Driscoll D, Foster C, Froelicher E, Gordon N, Pate R, Rippe J, Bazzarre T. Recommendations for cardiovascular screening, staffing, and emergency policies at health/fitness facilities. Circulation. 1998 Jun 9;97(22):2283-93.</citation>
    <PMID>9631884</PMID>
  </reference>
  <reference>
    <citation>Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol. 2006 Oct;21(7):623-43. Epub 2006 Oct 2.</citation>
    <PMID>17014981</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

